Skip to search formSkip to main contentSkip to account menu

enzalutamide

Known as: Benzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl- 
An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a… 
National Institutes of Health

Related topics

Related topics

6 relations
Androgen Receptor Antagonists [MoA]NCIt Antineoplastic Agent Terminologyenzalutamide 40 MG Oral Capsuleenzalutamide 40 MG Oral Capsule [Xtandi]

Broader (1)

MDV 3100

Narrower (1)

Xtandi

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Primary resistance to androgen receptor (AR)-directed therapies in metastatic castration-resistant prostate cancer (mCRPC) is… 
Review
2018
Review
2018
Genomic Markers in Prostate Cancer Decision Making.
Highly Cited
2017
Highly Cited
2017
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Abstract Background There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate… 
Highly Cited
2017
Highly Cited
2017
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Highly Cited
2016
Highly Cited
2016
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
PURPOSE Enzalutamide, a potent oral androgen receptor inhibitor, improves survival in men with metastatic castration-resistant… 
Highly Cited
2014
Highly Cited
2014
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
IntroductionThe androgen receptor (AR) is widely expressed in breast cancers and has been proposed as a therapeutic target in… 
Highly Cited
2014
Highly Cited
2014
Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer
Purpose: Enzalutamide, a second-generation antiandrogen, was recently approved for the treatment of castration-resistant prostate… 
Highly Cited
2014
Highly Cited
2014
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
Efficacy of Enzalutamide (ENZ) in castration resistant prostate cancer (CRPC) patients is short-lived. Immunotherapy like T cell… 
Review
2014
Review
2014
Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone
The FDA approvals of enzalutamide and abiraterone have rapidly changed the clinical landscape of prostate cancer treatment. Both… 
Highly Cited
2014
Highly Cited
2014
Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells
Use of enzalutamide has improved the treatment of advanced prostate cancer. However, resistance to enzalutamide can develop… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)